Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
5th January 2021 | Mark E Saad | 8,227 | Grant/award etc. | $0.00 | |
18th November 2020 | Roger Jeffs | 1,387,500 | Other acquisition or disposition | $6.00 | $8,325,000.00 |
12th October 2020 | Mark E Saad | 100,000 | Grant/award etc. | $0.00 | |
19th August 2020 | Mark Coleman | 397,998 | Bona fide gift | $0.00 | |
19th August 2020 | Mark Coleman | 397,998 | Bona fide gift | $0.00 | |
29th June 2020 | Nick Pizzie | 777 | Open or private purchase | $76.64 | $59,549.28 |
29th June 2020 | Mark Coleman | 650 | Open or private purchase | $78.50 | $51,025.00 |
10th January 2020 | Roger Jeffs | 11,000 | Exercise of derivative | $4.95 | $54,450.00 |
10th January 2020 | Roger Jeffs | 9,127 | Exercise of derivative | $9.00 | $82,143.00 |
10th January 2020 | Roger Jeffs | 34,866 | Exercise of derivative | $12.95 | $451,514.70 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company was founded by Herriot Tabuteau on January 12, 2012.